7-, 8-, and 10-substituted amino triazolo quinazoline derivatives as adenosine receptor antagonists, pharmaceutical compositions and their use

US12263171B2 · kind B2 · utility

Assignee

• Merck Sharp & Dohme LLC · US

Inventors

• Yonglian Zhang · Metuchen, US
• Amjad Ali · Freehold, US
• Jared N. Cumming · Garwood, US
• Duane DeMong · Somerville, US
• Qiaolin Deng · Edison, US
• Thomas H. Graham · Somerville, US
• Elisabeth Hennessy · Weston, US
• Matthew A. Larsen · Dedham, US
• Kun Liu · Edison, US
• Ping Liu · Shanghai, CN
• Umar Faruk Mansoor · Framingham, US
• Jianping Pan · Monmouth Junction, US
• Christopher W. Plummer · Hoboken, US
• Aaron Sather · Melrose, US
• Uma Swaminathan · Riverview, US
• Huijun Wang · Westfield, US

Key dates

• Filing date: Nov 26, 2019
• Grant date: Apr 1, 2025
• Expiry date: Apr 10, 2042

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D519/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

In its many embodiments, the present invention provides certain 7-, 8-, and 10-substituted amino triazolo quinazoline derivatives of Formula (I): or a pharmaceutically acceptable salt thereof, wherein ring A, R1, R2, and R4 are as defined herein, pharmaceutical compositions comprising one or more such compounds (alone and in combination with one or more other therapeutic agents), and methods for their preparation and use, alone and in combination with other therapeutic agents, as antagonists of A2a and/or A2b receptors, and their use in the treatment of a variety of diseases, conditions, or disorders that are mediated, at least in part, by the adenosine A2a receptor and/or the adenosine A2b receptor.